Recurrent Glioblastomas

The National Institutes of Health (NIH), specifically the National Institute of Neurological Disorders and Stroke (NINDS), published this Special Notice on March 31, 2026, regarding a non-competitive sole source contract award for clinical monitoring services. The solicitation (NIMH26000869) is designated as an 8(a) small business set-aside under NAICS code 541715. The contract pertains to a Phase II clinical trial investigating LMP744, a novel CMYC/TOPOISOMERASE 1 inhibitor, in patients with recurrent glioblastoma. The government has identified Emmes Company, LLC as the sole source contractor capable of performing the required services due to the sensitive nature of clinical data abstraction and the trial's unique requirements.

The primary objective of this contract is to support clinical monitoring and data management services for a Phase II clinical trial enrolling 40 patients with recurrent glioblastoma. The contractor must provide clinical data management, monitoring, data collection, abstraction, validation, and communication support, with performance occurring both onsite at the NIH campus in Bethesda, Maryland and remotely over an estimated 1,634 hours across the five-year contract period. The base performance period runs from May 1, 2026 through April 30, 2027, with four optional renewal years available. Interested parties must submit capability statements, proposals, or quotations to Joe Kennedy (joseph.kennedy@nih.gov) by April 15, 2026 at 12:00 PM EST, and submissions must include unit pricing, delivery terms, UEI, TIN, business size certification, and SAM registration confirmation. Eligible contractors must be small businesses registered in the System for Award Management (SAM) and must demonstrate capability in managing sensitive clinical trial data for this Phase II study evaluating the efficacy and safety of LMP744 in recurrent glioblastoma patients.